Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
Business Wire (Thu, 30-Jan 4:05 PM ET)
Business Wire (Thu, 30-Jan 8:05 AM ET)
Benzinga (Sun, 26-Jan 9:45 AM ET)
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Guardant Health (GH)
TipRanks (Sun, 26-Jan 4:20 AM ET)
Business Wire (Thu, 23-Jan 8:05 AM ET)
Business Wire (Tue, 21-Jan 8:05 AM ET)
Business Wire (Thu, 16-Jan 8:05 AM ET)
Business Wire (Tue, 14-Jan 3:56 PM ET)
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results
Business Wire (Mon, 13-Jan 7:00 AM ET)
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Guardant Health trades on the NASDAQ stock market under the symbol GH.
As of January 31, 2025, GH stock price declined to $46.95 with 1,570,687 million shares trading.
GH has a beta of 1.87, meaning it tends to be more sensitive to market movements. GH has a correlation of 0.13 to the broad based SPY ETF.
GH has a market cap of $5.80 billion. This is considered a Mid Cap stock.
Last quarter Guardant Health reported $191 million in Revenue and -$.45 earnings per share. This beat revenue expectation by $21 million and exceeded earnings estimates by $.29.
In the last 3 years, GH traded as high as $78.34 and as low as $15.81.
The top ETF exchange traded funds that GH belongs to (by Net Assets): IWM, VTI, VB, ARKG, VXF.
GH has outperformed the market in the last year with a price return of +110.9% while the SPY ETF gained +24.0%. GH has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +103.5% and +25.8%, respectively, while the SPY returned +4.1% and +1.7%, respectively.
GH support price is $47.84 and resistance is $52.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GH shares will trade within this expected range on the day.